Our Services
Medical Information
Helpful Resources
Published on: 9/13/2026
Emotional blunting on Lexapro (escitalopram) happens because increased serotonin activity can dampen the brain's reward and emotional processing circuits, muting sadness and pleasure alike, and this affects an estimated 40 to 60 percent of people taking SSRIs. Dose level matters a great deal, since higher doses are more strongly linked to feeling flat, and effects sometimes fade as your body adjusts during the first weeks. It is also important to distinguish medication side effects from lingering depressive symptoms like anhedonia, which can look nearly identical but call for a very different response. Options such as dose adjustment, switching antidepressants, adding an augmenting medication, or timing your dose differently may help, and several factors determine which fits your situation, so see below to understand more before changing anything on your own.
If numbness, apathy, or a loss of emotional range is affecting your relationships, work, or motivation, mapping your symptoms is a smart first step. A free, instant, online symptom check can help you sort out whether what you feel points more toward a medication effect, unresolved depression, or something else entirely, and it takes only a few minutes. Walking into your next appointment with that clarity makes it far easier to ask for the specific change you need.
Last reviewed for medical accuracy: 09/13/2026
Why Does Lexapro Make Me Feel Numb or Emotionally Flat?
Escitalopram (brand name Lexapro) is a popular SSRI (selective serotonin reuptake inhibitor) prescribed for depression and anxiety. While many people find relief, a common side effect is emotional blunting—feeling numb, “flat,” or less able to experience highs and lows. This response explains why it happens, how common it is, and what you can do about it.
Lexapro increases serotonin levels in the brain by blocking its reabsorption (reuptake). Serotonin is a key neurotransmitter that helps regulate mood, anxiety, sleep, and even appetite. By boosting serotonin:
However, raising serotonin can also dull some emotional responses.
Emotional blunting (or “flattening”) means feeling less intense emotions—both positive and negative. You might notice:
This effect can feel odd or worrying, especially if you started Lexapro hoping to regain emotional well-being.
Serotonin doesn’t work in isolation. It interacts with other brain chemicals (dopamine, norepinephrine) that govern reward, motivation, and emotional intensity. When Lexapro boosts serotonin:
Your brain’s attempt to rebalance neurotransmitters leads to a steadier but less reactive emotional state.
Studies and patient surveys suggest emotional blunting affects up to 40–60% of SSRI users. Factors influencing your risk include:
Not everyone feels numb—and for some, the benefit of reduced anxiety outweighs the cost of mild emotional flattening.
Emotional blunting can start 2–8 weeks after beginning Lexapro or adjusting your dose. In many people:
Keep a simple mood log to track when blunting is worst—this helps guide next steps.
Before making any changes, weigh:
Pros of staying on Lexapro
Cons of persistent blunting
Discussing these pros and cons with your doctor helps find the right balance.
If emotional blunting feels too strong, consider these options under medical guidance:
Dose Adjustment
• Lowering your dose may reduce blunting while keeping mood benefits.
• Small adjustments (e.g., 5 mg steps) can make a difference.
Medication Switch
• Another SSRI or SNRI (serotonin-norepinephrine reuptake inhibitor) might cause less blunting.
• Bupropion (Wellbutrin) or mirtazapine may offer different side-effect profiles.
Add-On Therapy
• Adding a low-dose stimulant or bupropion can boost motivation and emotional range.
• Agents like buspirone might counteract blunting.
Non-Drug Approaches
• Cognitive Behavioral Therapy (CBT) to strengthen emotional skills.
• Mindfulness, breathwork, or graded exposure to positive experiences.
• Regular exercise, social activities, and creative outlets.
Never adjust or stop medication without your doctor’s approval.
Proactive tracking and discussion help tailor your treatment:
Open communication ensures you don’t endure unnecessary side effects.
While emotional blunting itself is generally not life-threatening, watch for:
If you notice serious symptoms, contact emergency services or go to the nearest hospital.
If you’re unsure whether your symptoms are serious or how best to manage them, you might consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker. This tool can help you:
Always discuss any troubling side effects or persistent emotional changes with your prescribing clinician. Be honest about:
Your doctor can recommend safe strategies to optimize your treatment plan.
Lexapro helps many people overcome depression and anxiety, but emotional blunting is a real and sometimes distressing side effect. Understanding why it happens, how common it is, and what you can do empowers you to work with your doctor toward a treatment that best supports both stability and emotional richness.
If you experience any life-threatening or serious symptoms, please speak to a doctor or call emergency services immediately. Your health and safety are the top priority.
(References)
* Burstein O, Franko M, Gale E, Handelsman A, Barak S, Motsan S, Shamir A, Toledano R, Simhon O, Hirshler Y, Chen G, Doron R. Escitalopram and NHT normalized stress-induced anhedonia and molecular neuroadaptations in a mouse model of depression. PLoS One. 2017;12(11):e0188043. doi: 10.1371/journal.pone.0188043. Epub 2017 Nov 15. PMID: 29141007; PMCID: PMC5687745.
* Takahashi M, Tabu H, Ozaki A, Hamano T, Takeshima T, REBORN study group. Antidepressants for Depression, Apathy, and Gait Instability in Parkinson's Disease: A Multicenter Randomized Study. Intern Med. 2019 Feb 1;58(3):361-368. doi: 10.2169/internalmedicine.1359-18. Epub 2018 Aug 24. PMID: 30146591; PMCID: PMC6395136.
* Jha MK, Trivedi MH. Pharmacogenomics and Biomarkers of Depression. Handb Exp Pharmacol. 2019;250:101-113. doi: 10.1007/164_2018_171. PMID: 30341727.
* Peters EM, Balbuena L, Lodhi RJ. Emotional blunting with bupropion and serotonin reuptake inhibitors in three randomized controlled trials for acute major depressive disorder. J Affect Disord. 2022 Dec 1;318:29-32. doi: 10.1016/j.jad.2022.08.066. Epub 2022 Aug 24. PMID: 36029876.
* Abdelkawy YS, Elharoun M, Sheta E, Abdel-Raheem IT, Nematalla HA. Liraglutide and Naringenin relieve depressive symptoms in mice by enhancing Neurogenesis and reducing inflammation. Eur J Pharmacol. 2024 May 15;971:176525. doi: 10.1016/j.ejphar.2024.176525. Epub 2024 Mar 30. PMID: 38561101.
* Harding R, Singer N, Wall MB, Hendler T, Erritzoe D, Nutt D, Carhart-Harris R, Roseman L. Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises. Mol Psychiatry. 2025 Jul;30(7):3188-3196. doi: 10.1038/s41380-025-03035-8. Epub 2025 Apr 26. PMID: 40281226; PMCID: PMC12185350.
* Gericke J, Steyn SF, Viljoen FP, Harvey BH. Neuro-Inflammatory and Behavioral Changes Are Selectively Reversed by Sceletium tortuosum (Zembrin(®)) and Mesembrine in Male Rats Subjected to Unpredictable Chronic Mild Stress. Cells. 2025 Jul 4;14(13). doi: 10.3390/cells14131029. Epub 2025 Jul 4. PMID: 40643548; PMCID: PMC12249403.
* Rowe J, Nogovitsyn N, Mazurka R, Squires SD, Hassel S, Poppenk J, Dunlop K, Zamyadi M, Milev RV, Foster JA, Arnott SR, Lam RW, Uher R, Rotzinger S, Kennedy SH, Frey BN, Harkness KL. Latent Profile Analysis of Childhood Maltreatment and Neural Markers in Depression. JAMA Netw Open. 2025 Aug 1;8(8):e2525147. doi: 10.1001/jamanetworkopen.2025.25147. Epub 2025 Aug 1. PMID: 40758349; PMCID: PMC12322798.
* Ruanpang J, Thongta N, Vattarakorn A, Ngampramuan S, Pariwatcharakul P, Tapechum S, Care C, Pakaprot N. Cannabidiol reverses depression-like behaviors by enhancing hippocampal synaptic plasticity in rats with chronic restraint stress. Vet World. 2025 Sep;18(9):2823-2838. doi: 10.14202/vetworld.2025.2823-2838. Epub 2025 Sep 23. PMID: 41113223; PMCID: PMC12535449.
* Uher R, Rizvi SJ, Quilty LC, Pavlova B, Nunes A, Foster JA, Lam RW, Milev R, Müller DJ, Taylor V, Soares CN, Rotzinger S, Kennedy SH, Frey BN. Which aspects of anhedonia predict response to pharmacotherapy in major depressive disorder? Psychol Med. 2025 Dec 29;56:e2. doi: 10.1017/S0033291725102894. Epub 2025 Dec 29. PMID: 41459591; PMCID: PMC13092992.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.